Expert Insights into Management of Advanced
Triple Negative Breast Cancer

Access presentation PDF here (opens in new window).

For this first installment of a three webinar series, listen to Dr. Arays from the University of Kentucky Markey Cancer Center provide an overview of the biology of triple negative breast cancer (TNBC), discuss current treatment options for early stage/locally advanced TNBC, and discuss options for advanced or unresectable TNBC.

Key learnings include:

1. The percentage of patients who will relapse within 5 years of their initial diagnosis of TNBC
2. The benefit of neoadjuvant chemotherapy compared with adjuvant chemotherapy
3. Indications to perform genetic testing for ‘high penetrance breast cancer susceptibility genes
4. Improved outcomes in TNBC patients with additions of certain medications to standard chemotherapies

Featured Speaker

Ruta Arays, MD, PhD, MPH

Professor of Medicine and Neurology
Assistant Professor, Division of Medical Oncology
University of Kentucky Markey Cancer Center

Dr. Ruta Arays is an assistant professor of hematology-oncology with a specific interest in breast cancer and melanoma at the University of Kentucky. She completed her Doctor of Pharmacy degree at the University of Cincinnati in 2010 and then received her Doctor of Medicine degree at the University of Toledo College of Medicine. She completed residency in Internal Medicine at Riverside Methodist Hospital in Columbus, Ohio in 2017. Subsequently, she went on to do hematology-oncology fellowship and finished her first year at the University of Kentucky. She completed her fellowship at West Virginia University where she moved to be with family. She was a practicing attending at West Virginia University after her fellowship, and when the opportunity arose to return to Kentucky she and her husband were eager to join the growing practice and community in Lexington. She currently sees breast and lung cancer patients as well as provide care to melanoma patients.

All Sessions